LUIS ANTONIO
CORCHETE SÁNCHEZ
Instituto de Investigación Biomédica de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (19)
2023
2022
-
Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells
Therapeutic Advances in Hematology, Vol. 13
-
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
Experimental Hematology and Oncology, Vol. 11, Núm. 1
-
TCL-318 Evaluation of the Antitumor Activity of Amiloride in Peripheral T-Cell Lymphomas Using In-Vitro Models
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S399
2021
-
Patterns of incidental perineural invasion and prognosis in cutaneous squamous cell carcinoma: A multicenter, retrospective cohort study
Journal of the American Academy of Dermatology, Vol. 84, Núm. 6, pp. 1708-1712
2020
-
Systematic comparison and assessment of RNA-seq procedures for gene expression quantitative analysis
Scientific Reports, Vol. 10, Núm. 1
2019
-
Factors regulating microRNA expression and function in multiple myeloma
Non-coding RNA, Vol. 5, Núm. 1
-
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
Blood Cancer Journal, Vol. 9, Núm. 12
2018
-
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility
Haematologica, Vol. 103, Núm. 5, pp. 880-889
-
Polymorphisms in receptors involved in opsonic and nonopsonic phagocytosis, and correlation with risk of infection in oncohematology patients
Infection and Immunity, Vol. 86, Núm. 12
-
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles
Oncotarget, Vol. 9, Núm. 46, pp. 28083-28102
2017
-
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma
Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615
-
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors
Oncotarget, Vol. 8, Núm. 64, pp. 107685-107700
2016
-
Post-transcriptional modifications contribute to the upregulation of cyclin D2 in multiple myeloma
Clinical Cancer Research, Vol. 22, Núm. 1, pp. 207-217
-
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development
Journal of Hematology and Oncology, Vol. 9, Núm. 1
2015
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
Leukemia, Vol. 29, Núm. 5, pp. 1186-1194
2014
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234